Renos Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Net Worth -11.15%
- Total Assets 32.34%
About Renos Pharma
Renos Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 March 2016 (Eight years and ten months 24 days old ). Its registered office is in Palakkad, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Achuthannair, Sudheesh Krishnan, Girishkumar Mukkattu, and Four other members serve as directors at the Company.
Company Details
-
Location
Palakkad, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397KL2016PTC040395
-
Company No.
040395
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Mar 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Renos Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Achuthannair
|
Managing Director | 17-Mar-2016 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Sunil Dayananda
|
Director | 16-May-2016 | Current |
|
Sudheesh Krishnan
|
Director | 16-May-2016 | Current |
|
Girishkumar Mukkattu
|
Director | 16-May-2016 | Current |
|
Prasanth Padinareveettil
|
Director | 16-May-2016 | Current |
|
Jiji Chakkalakkal
|
Director | 17-Mar-2016 | Current |
|
Ranjith Rangarajan
|
Director | 16-May-2016 | Current |
Financial Performance of Renos Pharma.
Renos Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 11.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Renos Pharma?
In 2017, Renos Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Renos Pharma?
Unlock and access historical data on people associated with Renos Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Renos Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Renos Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.